Shubham Singh has been a journalist since 2018, covering business and consumer technology for leading media organizations such as India Today, CNBC-TV18, Zee News, and others. As a Reporter for Medtech Insight, he covers policy, regulation, and digital tech. Outside work, Shubham is an avid traveler, foodie, and fitness enthusiast, balancing his schedule with gym sessions, trekking, and OTT binge-watching.
Latest from Shubham Singh
Saudi Arabia’s proactive approach to health regulation prompted a lively debate among panelists at the Global Healthspan Summit 2025 in Riyadh.
Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.
Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.
Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.
The revival in funding of healthtech and pharma startups was significantly influenced by PharmEasy's $216m funding round, led by the Manipal Education and Medical Group (MEMG), albeit at a reduced valuation of $710m—a sharp decline from its previous $5.6bn valuation in 2021.
The Union Budget 2025 has overlooked several critical aspects that the medical devices and in-vitro diagnostics (IVD) sector had been expecting, industry leaders have pointed out.